肾衰竭患者他汀治疗的长期获益与安全性:目标试验模拟研究
该研究利用香港全港公共电子健康记录,纳入3019例LDL-C≥100 mg/dl且符合他汀治疗条件的肾衰竭患者,采用目标试验模拟框架比较他汀启动者与非启动者的长期结局。结果显示他汀治疗与主要心血管疾病和全因死亡风险降低相关,且未增加主要不良事件风险。
要点
- 肾衰竭患者启动他汀与主要心血管疾病风险降低相关(ITT HR 0.78,95%CI 0.62-0.98)。
- 他汀治疗与全因死亡风险降低相关(ITT HR 0.80,95%CI 0.68-0.95)。
- 未观察到肌病和肝功能障碍等主要不良事件风险显著增加。
核心结论
- 肾衰竭患者他汀治疗与心血管疾病和全因死亡风险降低相关,且未增加主要不良事件风险。
研究设计与样本
- 比较他汀启动者与非启动者,采用合并逻辑模型进行意向治疗(ITT)和符合方案(PP)分析。
主要发现
- 主要心血管疾病(心肌梗死、心力衰竭和卒中复合终点)风险显著降低:ITT HR 0.78(95%CI 0.62-0.98),PP HR 0.66(95%CI 0.50-0.87)。
- 全因死亡风险显著降低:ITT HR 0.80(95%CI 0.68-0.95),PP HR 0.60(95%CI 0.48-0.76)。
- PP分析标准化5年和10年绝对风险降低分别为7%(95%CI 3%-11%)和11%(95%CI 4%-18%)。
- 未观察到主要不良事件(肌病和肝功能障碍)风险显著增加。
临床怎么用
- 对于LDL-C≥100 mg/dl的肾衰竭患者,可考虑启动他汀治疗以降低心血管疾病和死亡风险。
- 治疗决策时应结合个体风险评估,并监测肌病和肝功能障碍等潜在不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Patients with kidney failure are at a higher risk of cardiovascular diseases, but the evidence for statin therapy remains inconclusive. The long-term benefits and risks of statin therapy in patients with kidney failure were analyzed using public electronic health records in Hong Kong. Statin therapy was associated with a lower risk of major cardiovascular diseases and all-cause mortality without a higher risk of major adverse events. BACKGROUND: Patients with kidney failure are at elevated risk of cardiovascular diseases. Although statins are commonly used to mitigate cardiovascular risk among the population with high risk, the evidence for initiating statin therapy among patients with kidney failure remains inconclusive. This study aimed to investigate the long-term benefits and risks associated with statin therapy in patients with kidney failure. METHODS: Using territory-wide public electronic health records in Hong Kong, 3019 statin-eligible individuals with kidney failure and elevated LDL cholesterol ≥100 mg/dl from January 2008 to December 2015 were included for analysis. The framework of target trial emulation was adopted to investigate the risk of the major cardiovascular diseases (i.e., a composite of myocardial infarction, heart failure, and stroke), all-cause mortality, and major adverse events (i.e., myopathies and liver dysfunction) between statin initiators and statin noninitiators. The pooled logistic model was used to obtain the hazard ratio for the outcomes of interest in both intention-to-treat (ITT) analysis and per-protocol (PP) analysis. RESULTS: Significant risk reduction associated with statin therapy (hazard ratio [95% confidence interval]) was observed for major cardiovascular diseases (ITT: 0.78 [0.62 to 0.98]; PP: 0.66 [0.50 to 0.87]) and all-cause mortality (ITT: 0.80 [0.68 to 0.95]; PP: 0.60 [0.48 to 0.76]). The standardized 5- and 10-year absolute risk reduction in PP analysis was 7% (3% to 11%) and 11% (4% to 18%), respectively. No significant risks for the major adverse events were observed. CONCLUSIONS: Statin therapy was associated with lower risks of cardiovascular diseases and all-cause mortality in patients with kidney failure without a higher risk of major adverse events.
引用
- Cheng FWT, Xu W, Tang SCW, et al. Long-Term Benefits and Safety of Statins in Patients with Kidney Failure: A Target Trial Emulation Study. J Am Soc Nephrol. 2024. PMID: 39480503. doi:10.1681/ASN.0000000554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。